CVM Stock Quote and Technical Analysis
Cel-Sci Corporation (CVM)|
► 0.241 (0.00)
Afterhours: N/A - N/A
|EPS: -0.045 (Current Year Estimated: -0.04)|
52 Week Range: 0.21 - 0.47
50 Day Moving Average: 0.2563
200 Day Moving Average: 0.2585
Pivot Point: Not Available
Login or signup free to Add "CVM" to your portfolio
CEL-SCI Corporation To Present At The Second Annual Marcum LLP MicroCap Conference
Thu, 23 May 2013 12:00:00 GMT
[PR Newswire] - VIENNA, Va., May 23, 2013 /PRNewswire/ -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that Geert Kersten, Chief Executive Officer, will present at the Second Annual Marcum LLP MicroCap Conference ...
CEL SCI CORP Financials
Fri, 17 May 2013 17:04:39 GMT
CEL-SCI Corporation Reports Second Quarter 2013 Financial Results
Fri, 10 May 2013 20:35:00 GMT
[Business Wire] - CEL-SCI Corporation reports financial results for the fiscal quarter ended March 31, 2013.
CEL SCI CORP Files SEC form 10-Q, Quarterly Report
Fri, 10 May 2013 13:31:07 GMT
CEL-SCI presents data on LEAPS vaccine
Mon, 06 May 2013 12:34:36 GMT
CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model
Mon, 06 May 2013 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis using the LEAPS technology , which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics.
NEW STORY CEL-SCI to Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4th
Fri, 03 May 2013 14:55:05 GMT
[at noodls] - CEL-SCI TO PRESENT AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS 100TH ANNUAL MEETING ON SATURDAY MAY 4TH Vienna, VA, May 3, 2013 -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that it will deliver ...
CEL-SCI To Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4th
Fri, 03 May 2013 13:11:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that it will deliver a presentation at the American Association of Immunologists 100th Annual Meeting at the Hawaii Convention Center in Honolulu, Hawaii.
Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!
Fri, 26 Apr 2013 12:15:00 GMT
Bullish $10 Million Bet Placed by CRO After CEL-SCI Acts to Accelerate Phase III Enrollment
Wed, 24 Apr 2013 11:01:00 GMT
[Marketwired] - In newly published news, CEL-SCI Corporation has provided investors a much needed update on the Phase III Clinical Trial of its investigational drug Multikine.
CEL-SCI provides update on phase III clinical trial of Multikine
Tue, 23 Apr 2013 12:05:00 GMT
CEL-SCI Corporation Provides Update on Phase III Clinical Trial
Tue, 23 Apr 2013 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today provided an update on the Phase III Clinical Trial of its investigational drug Multikine* for the treatment of head and neck cancer.
Three Biotech Stocks With Low Price But Great Potential
Tue, 16 Apr 2013 10:17:19 GMT
BioCryst Won't Profit From Bird Flu Outbreak in China
Mon, 08 Apr 2013 19:11:00 GMT
CEL-SCI Corporation Announces That NIAID Collaborators Have Submitted Bird Flu Study for Publication to Prestigious Scientific Journal
Mon, 08 Apr 2013 16:55:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that its collaborators at the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health, USA, have submitted for publication to a prestigious scientific journal the results from efficacy studies in animals of L.E.A.P.S.
CEL-SCI's Price Rebound Looks Strong
Thu, 04 Apr 2013 11:01:00 GMT
[Marketwired] - Anyone who has ever had a family member or friend afflicted with cancer knows first hand that the treatments they must endure seem far more devastating than the disease itself. An exciting video released ...
CEL-SCI Corporation Releases New Video on Its Website
Tue, 02 Apr 2013 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that it has released a new video about its investigational cancer drug Multikine* and the dedicated manufacturing facility to produce Multikine near Baltimore, MD, USA.
Cel-Sci Corp CEO Buys More Than 348K Shares and 4 Insider Trades to Note
Thu, 28 Mar 2013 13:15:09 GMT
Taglich Brothers Initiates Coverage on CEL-SCI Corporation
Mon, 04 Mar 2013 18:39:20 GMT
[Marketwired] - Taglich Brothers, Inc. announces it initiated coverage of CEL-SCI Corporation.
CEL-SCI Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan
Mon, 25 Feb 2013 15:00:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has added two additional Taiwanese clinical centers in CEL-SCI’s Phase III head and neck cancer clinical trial for Multikine® , the Company’s flagship investigational immunotherapy.
All Company News is Powered by Yahoo! Finance